Enhanced intracellular uptake and inhibition of NF‐κB activation by decoy oligonucleotide released from PLGA microspheres
- 8 February 2005
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 7 (6) , 771-781
Abstract
Background: Nuclear factor‐κB (NF‐κB) transcription factor regulates the expression of genes involved in immune response and inflammation. NF‐κB activity can be efficiently inhibited by double‐stranded oligodeoxynucleotides (ODNs). In the present study, we investigated the potential of poly(DL‐lactic‐co‐glycolic acid) (PLGA) microspheres as delivery system for an ODN against NF‐κB in RAW 264.7 macrophages stimulated with lipopolysaccharide (LPS).Methods: Microspheres encapsulating ODN were prepared by the multiple emulsion/solvent evaporation technique and characterised in terms of size, morphology, encapsulation efficiency and in vitro release profile. In vitro uptake after 4 h and activity of ODN released from microspheres were evaluated in RAW 264.7 macrophages stimulated with LPS for 24, 48 and 72 h.Results: We prepared microspheres with a high encapsulation efficiency showing a very slow and almost constant in vitro release of ODN for up to 1 month. ODN slowly released from microspheres translocated better into LPS‐stimulated cells as compared with naked ODN. Incubation of cells with ODN‐encapsulating microspheres resulted in a decrease of tumor necrosis factor‐alpha (TNF‐α) and nitrite production, inducible nitric oxide synthase (iNOS) protein expression, as well as NF‐κB/DNA‐binding activity. Similar results were obtained with naked ODN only at about 80 times higher concentrations.Conclusions: Our results suggest that PLGA microspheres could be a useful tool to improve pharmacokinetics of a ODN decoy to NF‐κB and may represent a promising strategy to effectively inhibit the transcriptional activity of NF‐κB in inflammatory process. Copyright © 2005 John Wiley & Sons, Ltd.Keywords
This publication has 29 references indexed in Scilit:
- NF-κB: a key role in inflammatory diseasesJournal of Clinical Investigation, 2001
- Phosphorylation Meets Ubiquitination: The Control of NF-κB ActivityAnnual Review of Immunology, 2000
- Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor ?B decoy oligodeoxynucleotides as a gene therapyArthritis & Rheumatism, 1999
- Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor modelGene Therapy, 1999
- NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic jointProceedings of the National Academy of Sciences, 1998
- NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune ResponsesAnnual Review of Immunology, 1998
- In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarctionNature Medicine, 1997
- Hypoxia Induces Cyclooxygenase-2 via the NF-κB p65 Transcription Factor in Human Vascular Endothelial CellsJournal of Biological Chemistry, 1997
- Regulation of Gene Expression with Double-Stranded Phosphorothioate OligonucleotidesScience, 1990
- Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B.Molecular and Cellular Biology, 1990